**NOTICE OF CONFIRMATION**

**OF SHARE CONSOLIDATION**

I, J. Scott Munro (Scott Munro), Chief Executive Officer and a Director of Adastra Labs Holdings Ltd. (the “**Company**”) pursuant to the upcoming share consolidation of the common shares of the Company (the “**Common** **Shares**”) confirm that:

1. The British Columbia Securities Commission, the Alberta Securities Commission, and the Ontario Securities Commission, in addition to  CDS as the clearing corporation have been notified by the Company of the upcoming consolidation;
2. The share consolidation is on the basis of 3:1; with each 3 (three) pre-consolidated Common Shares being consolidated into one (1) post consolidated Common Shares (the “**Share** **Consolidation**”);
3. The Share Consolidation will result in the number of issued and outstanding Common Shares being reduced from the current outstanding 130,001,985 Common Shares to approximately 43,333,995 Common Shares;
4. The Share Consolidation will result in the following changes to shares reserved for issuance (post-consolidation numbers are approximates rounded up):
* With respect of issued and outstanding Stock Options:

pre consolidated basis: 12,500,000

post consolidated basis: 4,166,667

* With respect of issued and outstanding Warrants:

pre consolidated basis: 25,152,378

post consolidated basis: 8,384,126

1. No fractional shares will be issued as a result of the Share Consolidation. Any fractional shares resulting from the Share Consolidation will be rounded up to the next whole Common Share, and no cash consideration will be paid in respect of fractional shares;
2. The new CUSIP and ISIN numbers for the Company’s new name (Phyto Extractions Inc.)

(“**Name** **Change**”) and the post Share Consolidation Common Shares will be 71945P103 and CA71945P1036 respectively; and

1. The record date for the Name Change and Consolidation is confirmed as April 8, 2021.

 Date: April 5, 2021

 Signed: /s/ Scott Munro

 (Signature)

 Scott Munro

 Director and Chief Executive Officer